Jan 26 (Reuters) - The U.S. Food and Drug Administration approved Rockwell Medical Inc's drug for treating iron loss in chronic kidney disease patients on dialysis, sending the company's shares up about 15 percent in premarket trading.
The drug, Triferic, replaces the 5-7 mg of iron patients tend to lose during each dialysis session.
16:51 Scottrade Sale Nearly Doubles Owner’s Wealth to $4 Billion9
21:31 Time Warner jumps after hours on report it could sell for $110 per share to AT&T1
18:04 US stocks hold higher after release of Fed's Beige Book; energy rises 2%
17:06 Harley-Davidson says laid off temp workers last quarter